Evaluation of the use of low-molecular-weight heparin for venous thromboembolism prophylaxis in medical patients

被引:1
|
作者
du Plessis, J. A. [1 ]
van Blydenstein, S. A. [2 ,3 ]
Wong, M. [2 ,3 ]
机构
[1] Univ Witwatersrand, Fac Hlth Sci, Sch Clin Med, Johannesburg, South Africa
[2] Univ Witwatersrand, Chris Hani Baragwanath Acad Hosp, Dept Internal Med, Johannesburg, South Africa
[3] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa
来源
SAMJ SOUTH AFRICAN MEDICAL JOURNAL | 2020年 / 110卷 / 03期
关键词
UNFRACTIONATED HEPARIN; COST-EFFECTIVENESS; RISK; PREVENTION; THROMBOSIS; DRUG; VTE;
D O I
10.7196/SAMJ.2020.v110i3.14279
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Venous thromboembolism (VTE) complicates a significant proportion of medical admissions. As well as increasing patient morbidity, pulmonary embolism is one of the commonest preventable causes of in-hospital death. An increase in the use of pharmacological preventive measures has been advocated in recent years. South African (SA) and international guidelines have been published in an effort to promote the safe use of VTE prophylaxis. Objectives. To describe adherence to both local and international recommendations for VTE prophylaxis in an SA hospital with regard to appropriateness of the decision to prescribe or withhold low-molecular-weight heparin (LMWH), and to observe the practice of dose adjustment in special population groups. Methods. This was a prospective, observational study, and data were collected from consenting adults admitted to the medical wards. We assessed the patients' VTE risk, bleeding risk and the presence of contraindications at the time of LMWH prescription as well as the dose prescribed, specifically taking into consideration adjustment for renal dysfunction and obesity. Results. Three hundred and fifty-two patients were enrolled, of whom 51.4% were male and 58.5% received LMWH. Primary outcomes. The appropriate overall decision according to both SA and international guidelines was made in 254 cases (72.2%). The inappropriate decision according to both guidelines was made in 79 cases (22.4%) and the appropriate decision according to one guideline only was made in 18 cases (5.1%), while 1 case (0.3%) was not categorised. Contraindications to VTE prophylaxis were present in 35 patients (9.9%), but 9 of these patients nevertheless received LMWH. An incorrect dose was prescribed in 36 cases (17.5%), the most common reason being an inappropriate reduction in the dose in mild renal dysfunction. Secondary outcomes. Other medications that may have increased bleeding risk were prescribed in 46 patients who received LMWH (22.3%). Mechanical prophylaxis was indicated in 25 (7.1%) of the total sample; however, none received this. Conclusions. Overall adherence to published guidelines for VTE prophylaxis has improved compared with other published reviews on the topic, but documentation of patients' VTE risk in files is poor. Overuse in low-risk patients may be an unintended consequence of the widespread advocacy of LMWH use in hospital, highlighting the importance of adequate VTE risk stratification. Incorrect dosing in special population groups is an issue that needs to be addressed, as is non-utilisation of mechanical prophylaxis methods.
引用
收藏
页码:235 / 242
页数:8
相关论文
共 50 条
  • [31] Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis: a trial sequential analysis
    Hung, Kuo-Chuan
    Chen, I-Wen
    Liu, Ping-Hsin
    [J]. INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (03) : 1839 - 1840
  • [32] Low-Molecular-Weight Heparin is Superior for Venous Thromboembolism Prophylaxis in High-Risk Geriatric Trauma Patients
    Deusenberry, Christina
    Bardsley, Casey
    Hobbs, Gerald
    Wilson, Alison M.
    Bardes, James
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 231 (04) : E61 - E61
  • [33] LOW-MOLECULAR-WEIGHT HEPARIN IN THE PROPHYLAXIS OF VENOUS THROMBOSIS - A METAANALYSIS
    ROSENDAAL, FR
    NURMOHAMED, MT
    BULLER, HR
    DEKKER, E
    VANDENBROUCKE, JP
    BRIET, E
    [J]. THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 927 - 927
  • [34] Heparin and low-molecular-weight heparin therapy for venous thromboembolism: Will unfractionated heparin survive?
    Hull, RD
    Pineo, GF
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2004, 30 : 11 - 23
  • [35] LONG-TERM PROPHYLAXIS OF THROMBOEMBOLISM WITH LOW-MOLECULAR-WEIGHT HEPARIN
    HARENBERG, J
    LEBER, G
    AUGUSTIN, J
    RAEDSCH, R
    SCHWARZ, F
    STIEHL, A
    ZIMMERMANN, R
    [J]. KLINISCHE WOCHENSCHRIFT, 1987, 65 (07): : 331 - 337
  • [36] A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma
    Geerts, WH
    Jay, RM
    Code, KI
    Chen, EL
    Szalai, JP
    Saibil, EA
    Hamilton, PA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10): : 701 - 707
  • [37] Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
    Bergqvist, D
    Benoni, G
    Bjorgell, O
    Fredin, H
    Hedlundh, U
    Nicolas, S
    Nilsson, P
    Nylander, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10): : 696 - 700
  • [38] Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?
    Strebel, N
    Prins, M
    Agnelli, G
    Büller, HR
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (13) : 1451 - 1456
  • [39] Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin
    Andersen, Anita Sylvest
    Berthelsen, Jorgen G.
    Bergholt, Thomas
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2010, 89 (01) : 15 - 21
  • [40] Prevention of venous thromboembolism in patients undergoing laparoscopic surgery with low-molecular-weight heparin
    Baca, I
    Schneider, B
    Misselwitz, F
    [J]. THROMBOSIS AND HAEMOSTASIS, 1997, : PS511 - PS511